RhumbLine Advisers’s Corbus Pharmaceuticals CRBP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.33K | Sell |
482
-14,657
| -97% | -$101K | ﹤0.01% | 3950 |
|
|
2025
Q1 | $80.4K | Buy |
15,139
+25
| +0.2% | +$133 | ﹤0.01% | 3457 |
|
|
2024
Q4 | $178K | Buy |
15,114
+423
| +3% | +$4.99K | ﹤0.01% | 3257 |
|
|
2024
Q3 | $303K | Buy |
14,691
+588
| +4% | +$12.1K | ﹤0.01% | 3020 |
|
|
2024
Q2 | $638K | Buy |
+14,103
| New | +$638K | ﹤0.01% | 2495 |
|
|
2021
Q2 | – | Sell |
-3,363
| Closed | -$199K | – | 3015 |
|
|
2021
Q1 | $199K | Sell |
3,363
-67
| -2% | -$3.97K | ﹤0.01% | 2831 |
|
|
2020
Q4 | $129K | Buy |
3,430
+466
| +16% | +$17.5K | ﹤0.01% | 2935 |
|
|
2020
Q3 | $160K | Sell |
2,964
-431
| -13% | -$23.3K | ﹤0.01% | 2752 |
|
|
2020
Q2 | $855K | Buy |
3,395
+663
| +24% | +$167K | ﹤0.01% | 2106 |
|
|
2020
Q1 | $430K | Buy |
2,732
+37
| +1% | +$5.82K | ﹤0.01% | 2232 |
|
|
2019
Q4 | $441K | Buy |
2,695
+80
| +3% | +$13.1K | ﹤0.01% | 2421 |
|
|
2019
Q3 | $382K | Sell |
2,615
-13
| -0.5% | -$1.9K | ﹤0.01% | 2445 |
|
|
2019
Q2 | $546K | Buy |
2,628
+377
| +17% | +$78.3K | ﹤0.01% | 2328 |
|
|
2019
Q1 | $469K | Buy |
2,251
+95
| +4% | +$19.8K | ﹤0.01% | 2349 |
|
|
2018
Q4 | $378K | Buy |
2,156
+746
| +53% | +$131K | ﹤0.01% | 2426 |
|
|
2018
Q3 | $319K | Sell |
1,410
-107
| -7% | -$24.2K | ﹤0.01% | 2485 |
|
|
2018
Q2 | $230K | Buy |
1,517
+97
| +7% | +$14.7K | ﹤0.01% | 2670 |
|
|
2018
Q1 | $260K | Buy |
1,420
+185
| +15% | +$33.9K | ﹤0.01% | 2508 |
|
|
2017
Q4 | $263K | Sell |
1,235
-287
| -19% | -$61.1K | ﹤0.01% | 2520 |
|
|
2017
Q3 | $326K | Buy |
1,522
+23
| +2% | +$4.93K | ﹤0.01% | 2519 |
|
|
2017
Q2 | $283K | Buy |
+1,499
| New | +$283K | ﹤0.01% | 2585 |
|